Jean-Michel Dogné to Female
This is a "connection" page, showing publications Jean-Michel Dogné has written about Female.
Connection Strength
0.051
-
Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021 Dec; 10(1):1495-1498.
Score: 0.003
-
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses. 2021 07 14; 13(7).
Score: 0.003
-
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021 Sep; 27(9):1351.e5-1351.e7.
Score: 0.003
-
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. Eur J Drug Metab Pharmacokinet. 2020 Dec; 45(6):703-713.
Score: 0.003
-
Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins. J Med Virol. 2021 04; 93(4):2262-2269.
Score: 0.003
-
Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thromb Res. 2021 01; 197:20-23.
Score: 0.003
-
Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study. Clin Chem Lab Med. 2020 09 25; 58(10):e193-e196.
Score: 0.003
-
High clinical performance and quantitative assessment of antibody kinetics using a dual recognition assay for the detection of SARS-CoV-2 IgM and IgG antibodies. Clin Biochem. 2020 Dec; 86:23-27.
Score: 0.003
-
Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. J Med Virol. 2021 02; 93(2):803-811.
Score: 0.003
-
Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps. Br J Clin Pharmacol. 2021 02; 87(2):674-682.
Score: 0.003
-
Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost. 2019 08; 17(8):1273-1287.
Score: 0.003
-
Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma. Int J Lab Hematol. 2019 Apr; 41(2):250-261.
Score: 0.003
-
Development and validation of a liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of serotonin and thromboxane B2 from activated platelets. Int J Lab Hematol. 2018 Dec; 40(6):663-671.
Score: 0.003
-
Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. Br J Clin Pharmacol. 2018 07; 84(7):1544-1556.
Score: 0.003
-
Fast, asymmetric and nonhomogeneous clearance of SiC nanoaerosol assessed by micro-particle-induced x-ray emission. Nanomedicine (Lond). 2018 Jan; 13(2):145-155.
Score: 0.002
-
Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thromb Res. 2017 Aug; 156:142-148.
Score: 0.002
-
Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates. Blood Transfus. 2018 02; 16(2):163-172.
Score: 0.002
-
Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis. 2017 Feb; 43(2):224-232.
Score: 0.002